1.0Québec Cancer Consortiumhttps://www.cqc-qcc.ca/en/rich600338<blockquote class="wp-embedded-content" data-secret="OTWugN2sKu"><a href="https://www.cqc-qcc.ca/en/2021/10/a-promising-study-from-astrazeneca/">A promising study from AstraZeneca</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://www.cqc-qcc.ca/en/2021/10/a-promising-study-from-astrazeneca/embed/#?secret=OTWugN2sKu" width="600" height="338" title="“A promising study from AstraZeneca” — Québec Cancer Consortium" data-secret="OTWugN2sKu" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script> /*! This file is auto-generated */ !function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document); //# sourceURL=https://www.cqc-qcc.ca/wp-includes/js/wp-embed.min.js </script> https://www.cqc-qcc.ca/wp-content/uploads/2021/01/john_stagg.jpeg1280909Preliminary results from Astra Zeneca’s COAST Phase II trial shows that anti-CD73 therapy, developed by Dr. John Stagg and his team, increases the efficacy of IMFINZI (durvalumab) in lung cancer patients. His discoveries led to the development of several therapeutic agents targeting the adenosine pathway. Read more about the study here